Trial · NCT03537508
Results by group164
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 164
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination | Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) | Serogroup A | 79.4 | 95% Confidence Interval 75.6 to 82.9 | percentage of participants |
| Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination | Group 2a: MENVEO (Post 12-month Vaccination) | Serogroup A | 77.6 | 95% Confidence Interval 71.5 to 82.9 | percentage of participants |
| Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination | Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) | Serogroup C | 97.0 | 95% Confidence Interval 95.1 to 98.3 | percentage of participants |
| Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination | Group 2a: MENVEO (Post 12-month Vaccination) | Serogroup C | 88.2 | 95% Confidence Interval 83.4 to 92.0 | percentage of participants |
| Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination | Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) | Serogroup Y | 96.4 | 95% Confidence Interval 94.4 to 97.8 | percentage of participants |
| Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination | Group 2a: MENVEO (Post 12-month Vaccination) | Serogroup Y | 92.3 | 95% Confidence Interval 88.1 to 95.4 | percentage of participants |
| Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination | Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) | Serogroup W | 97.6 | 95% Confidence Interval 95.9 to 98.7 | percentage of participants |
| Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination | Group 2a: MENVEO (Post 12-month Vaccination) | Serogroup W | 96.4 | 95% Confidence Interval 93.3 to 98.3 | percentage of participants |
| Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination | Group 1: MenACYW Conjugate Vaccine | Serogroup A | 77.9 | 95% Confidence Interval 75.0 to 80.7 | percentage of participants |
| Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination | Group 2: MENVEO | Serogroup A | 67.7 | 95% Confidence Interval 63.0 to 72.2 | percentage of participants |
| Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination | Group 1: MenACYW Conjugate Vaccine | Serogroup C | 99.0 | 95% Confidence Interval 98.1 to 99.6 | percentage of participants |
| Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination | Group 2: MENVEO | Serogroup C | 91.2 | 95% Confidence Interval 88.1 to 93.7 | percentage of participants |
| Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination | Group 1: MenACYW Conjugate Vaccine | Serogroup Y | 98.3 | 95% Confidence Interval 97.1 to 99.0 | percentage of participants |
| Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination | Group 2: MENVEO | Serogroup Y | 91.7 | 95% Confidence Interval 88.7 to 94.2 | percentage of participants |
| Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination | Group 1: MenACYW Conjugate Vaccine | Serogroup W | 98.6 | 95% Confidence Interval 97.6 to 99.3 | percentage of participants |
| Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination | Group 2: MENVEO | Serogroup W | 92.9 | 95% Confidence Interval 90.1 to 95.1 | percentage of participants |
| Groups 1 and 2: Percentage of Participants Who Achieved Anti-Hepatitis B Antibody Concentrations >=10 Milli-International Units Per Milliliter (mIU/mL) at Day 30 Post 6-Month Vaccination | Group 1: MenACYW Conjugate Vaccine | 98.6 | 95% Confidence Interval 97.4 | percentage of participants | |
| Groups 1 and 2: Percentage of Participants Who Achieved Anti-Hepatitis B Antibody Concentrations >=10 Milli-International Units Per Milliliter (mIU/mL) at Day 30 Post 6-Month Vaccination | Group 2: MENVEO | 98.0 | 95% Confidence Interval 95.9 | percentage of participants | |
| Groups 1 and 2: Percentage of Participants Who Achieved Anti-Polyribosyl-Ribitol (PRP) Antibody Concentrations >=0.15 and >=1.0 Microgram (mcg)/mL at Day 30 Post 6-Month Vaccination | Group 1: MenACYW Conjugate Vaccine | >=0.15 mcg/mL | 99.0 | 95% Confidence Interval 98.1 | percentage of participants |
| Groups 1 and 2: Percentage of Participants Who Achieved Anti-Polyribosyl-Ribitol (PRP) Antibody Concentrations >=0.15 and >=1.0 Microgram (mcg)/mL at Day 30 Post 6-Month Vaccination | Group 2: MENVEO | >=0.15 mcg/mL | 96.4 | 95% Confidence Interval 94.2 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03537508/results